ATE311188T1 - Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck - Google Patents
Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruckInfo
- Publication number
- ATE311188T1 ATE311188T1 AT94108687T AT94108687T ATE311188T1 AT E311188 T1 ATE311188 T1 AT E311188T1 AT 94108687 T AT94108687 T AT 94108687T AT 94108687 T AT94108687 T AT 94108687T AT E311188 T1 ATE311188 T1 AT E311188T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- group
- angiotensin
- compound
- combination
- Prior art date
Links
- 102000005862 Angiotensin II Human genes 0.000 title abstract 3
- 101800000733 Angiotensin-2 Proteins 0.000 title abstract 3
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title abstract 3
- 229950006323 angiotensin ii Drugs 0.000 title abstract 3
- 230000003042 antagnostic effect Effects 0.000 title abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 title 1
- 229960003963 manidipine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 150000001450 anions Chemical class 0.000 abstract 1
- 230000002213 calciumantagonistic effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13552493 | 1993-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311188T1 true ATE311188T1 (de) | 2005-12-15 |
Family
ID=15153791
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03001569T ATE372115T1 (de) | 1993-06-07 | 1994-06-07 | Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit einem diuretikum |
| AT03001570T ATE372116T1 (de) | 1993-06-07 | 1994-06-07 | Kombination von angiotensin-ii antagonistisch wirkenden benzimidazolen mit diuretika |
| AT94108687T ATE311188T1 (de) | 1993-06-07 | 1994-06-07 | Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck |
| AT96115146T ATE239471T1 (de) | 1993-06-07 | 1994-06-07 | Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03001569T ATE372115T1 (de) | 1993-06-07 | 1994-06-07 | Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit einem diuretikum |
| AT03001570T ATE372116T1 (de) | 1993-06-07 | 1994-06-07 | Kombination von angiotensin-ii antagonistisch wirkenden benzimidazolen mit diuretika |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96115146T ATE239471T1 (de) | 1993-06-07 | 1994-06-07 | Kombination eines angiotensin-ii antagonistisch wirkendes benzimidazols mit ein diuretikum |
Country Status (9)
| Country | Link |
|---|---|
| EP (6) | EP0753301B1 (de) |
| AT (4) | ATE372115T1 (de) |
| CA (1) | CA2125251C (de) |
| CY (1) | CY2370B1 (de) |
| DE (4) | DE69432644T2 (de) |
| DK (1) | DK0753301T3 (de) |
| ES (1) | ES2193217T3 (de) |
| PT (1) | PT753301E (de) |
| SG (1) | SG45336A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995033456A2 (en) * | 1994-06-07 | 1995-12-14 | Telor Ophthalmic Pharmaceuticals, Inc. | Reducing intraocular pressure using aryloxy- and aryl-acetic acids |
| US5763491A (en) * | 1994-12-09 | 1998-06-09 | The Regents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US6228873B1 (en) | 1994-12-09 | 2001-05-08 | The Regents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| ATE199495T1 (de) * | 1994-12-14 | 2001-03-15 | Enbalt Trading Ltd | Pharmazeutische zubereitung zur direktverpressung |
| PL185150B1 (pl) * | 1995-06-07 | 2003-03-31 | Searle & Co | Kompozycja farmaceutyczna do leczenia zaburzeń sercowo-naczyniowych |
| EP0831911B1 (de) * | 1995-06-07 | 2002-04-17 | G.D. Searle & Co. | Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist |
| AU5982296A (en) * | 1995-06-07 | 1996-12-30 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angi otensin ii antagonist and spironolactone |
| SI0914158T2 (sl) * | 1996-04-05 | 2006-04-30 | Takeda Chemical Industries Ltd | Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost |
| AU8996698A (en) * | 1997-09-10 | 1999-03-29 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
| EP1870098A3 (de) * | 1998-07-10 | 2010-07-07 | Novartis Ag | Kombinierte Verwendung von Valsartan und Kalziumkanalblocker für therapeutische Zwecke |
| TWI290470B (en) * | 1999-12-01 | 2007-12-01 | Sankyo Co | The composition for treating glaucoma |
| AU2001227084A1 (en) * | 2000-01-25 | 2001-08-07 | Japan Tobacco Inc. | N-arylhydrazide compounds and use thereof as drugs |
| WO2002034263A1 (fr) * | 2000-10-25 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Agents preventifs/remedes destines a l'hypertension portale |
| EP1353727A2 (de) * | 2000-12-01 | 2003-10-22 | Novartis AG | Kombinationen eines angiotensinrezeptor-hemmers und eines antihypertensiven medikaments oder eines statins, zur behandlung sexueller funktionsstörungen |
| AU2002349673A1 (en) * | 2001-12-03 | 2003-06-17 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
| KR20040080439A (ko) | 2001-12-12 | 2004-09-18 | 파마시아 코포레이션 | 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법 |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| NZ541454A (en) * | 2003-01-31 | 2008-04-30 | Daiichi Sankyo Co Ltd | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
| US7732467B2 (en) | 2003-05-15 | 2010-06-08 | Alzheimer's Institute Of America, Inc. | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| EP2214666B1 (de) | 2007-10-05 | 2013-12-11 | Alzheimer's Institute of America, Inc. | Verfahren zur reduzierung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliose mit (-)-nilvadipin-enantiomer |
| UY32017A (es) | 2008-07-31 | 2010-02-26 | Takeda Pharmaceutical | Composición farmacéutica sólida |
| UY32126A (es) | 2008-09-25 | 2010-04-30 | Takeda Pharmaceutical | Composición farmacéutica sólida |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| WO2010126168A2 (en) * | 2009-04-30 | 2010-11-04 | Takeda Pharmaceutical Company Limited | Solid preparation |
| TR201004754A1 (tr) * | 2010-06-11 | 2012-01-23 | Sanovel �La� San. Ve T�C. A.�. | Yeni Farmasötik Kombinasyonlar |
| BR112014027618A2 (pt) | 2012-05-07 | 2017-06-27 | Bayer Pharma AG | processo para a fabricação de uma forma de dosagem farmacêutica compreendendo nifedipina e candesartan cilexetil |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2016710A1 (en) * | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
| IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| DK0461039T3 (da) * | 1990-06-08 | 1999-06-14 | Hoechst Marion Roussel Inc | Nye benzimidazolafledte forbindelser, fremgangsmåde til deres fremstilling, de opnåede mellemprodukter, deres anvendelse so |
| JP3398379B2 (ja) * | 1990-12-14 | 2003-04-21 | スミスクライン・ビーチャム・コーポレイション | アンジオテンシンｉｉ受容体遮断組成物 |
| FR2673427B1 (fr) * | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
| IL102183A (en) * | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
| TW300219B (de) * | 1991-09-14 | 1997-03-11 | Hoechst Ag | |
| TW284688B (de) * | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
| GB2270841A (en) * | 1992-09-09 | 1994-03-30 | Merck & Co Inc | Compositions for Treating vascular restenosis |
| AU5449194A (en) * | 1992-10-26 | 1994-05-24 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
| WO1995021609A1 (en) * | 1994-02-08 | 1995-08-17 | Ciba-Geigy Ag | Treatment of normotensive glaucoma with angiotensin ii antagonists |
-
1994
- 1994-06-06 CA CA002125251A patent/CA2125251C/en not_active Expired - Lifetime
- 1994-06-07 EP EP96115146A patent/EP0753301B1/de not_active Revoked
- 1994-06-07 DE DE69432644T patent/DE69432644T2/de not_active Expired - Lifetime
- 1994-06-07 AT AT03001569T patent/ATE372115T1/de not_active IP Right Cessation
- 1994-06-07 EP EP10178599A patent/EP2277520A3/de not_active Withdrawn
- 1994-06-07 PT PT96115146T patent/PT753301E/pt unknown
- 1994-06-07 AT AT03001570T patent/ATE372116T1/de not_active IP Right Cessation
- 1994-06-07 EP EP03001569A patent/EP1306088B1/de not_active Expired - Lifetime
- 1994-06-07 DE DE69435021T patent/DE69435021T2/de not_active Expired - Lifetime
- 1994-06-07 SG SG1996003825A patent/SG45336A1/en unknown
- 1994-06-07 AT AT94108687T patent/ATE311188T1/de not_active IP Right Cessation
- 1994-06-07 EP EP07014995A patent/EP1844774A3/de not_active Ceased
- 1994-06-07 DE DE69434560T patent/DE69434560T2/de not_active Expired - Lifetime
- 1994-06-07 DE DE69435022T patent/DE69435022T2/de not_active Expired - Lifetime
- 1994-06-07 ES ES96115146T patent/ES2193217T3/es not_active Expired - Lifetime
- 1994-06-07 AT AT96115146T patent/ATE239471T1/de active
- 1994-06-07 DK DK96115146T patent/DK0753301T3/da active
- 1994-06-07 EP EP94108687A patent/EP0628313B1/de not_active Expired - Lifetime
- 1994-06-07 EP EP03001570A patent/EP1306089B1/de not_active Expired - Lifetime
-
2003
- 2003-08-04 CY CY0300054A patent/CY2370B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1306089B1 (de) | 2007-09-05 |
| EP0628313A1 (de) | 1994-12-14 |
| DE69432644D1 (de) | 2003-06-12 |
| DE69435022T2 (de) | 2008-05-29 |
| EP1306088B1 (de) | 2007-09-05 |
| EP0753301B1 (de) | 2003-05-07 |
| EP1844774A2 (de) | 2007-10-17 |
| EP0753301A1 (de) | 1997-01-15 |
| EP0628313B1 (de) | 2005-11-30 |
| EP2277520A2 (de) | 2011-01-26 |
| DE69435022D1 (de) | 2007-10-18 |
| CA2125251C (en) | 2005-04-26 |
| DE69434560D1 (de) | 2006-01-05 |
| EP2277520A3 (de) | 2011-08-24 |
| CA2125251A1 (en) | 1994-12-08 |
| DE69434560T2 (de) | 2006-06-08 |
| EP1306089A1 (de) | 2003-05-02 |
| ATE372115T1 (de) | 2007-09-15 |
| DE69435021D1 (de) | 2007-10-18 |
| DE69435021T2 (de) | 2008-05-29 |
| CY2370B1 (en) | 2004-06-04 |
| EP1844774A3 (de) | 2008-08-20 |
| DE69432644T2 (de) | 2003-11-27 |
| SG45336A1 (en) | 1998-01-16 |
| ATE239471T1 (de) | 2003-05-15 |
| ES2193217T3 (es) | 2003-11-01 |
| DK0753301T3 (da) | 2003-07-21 |
| EP1306088A1 (de) | 2003-05-02 |
| ATE372116T1 (de) | 2007-09-15 |
| PT753301E (pt) | 2003-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE311188T1 (de) | Kombination eines angiotensin-ii antagonistisch wirkenden benzimidazols mit manidipin zur behandlung von bluthochdruck | |
| ES2065182T3 (es) | Derivados de fenilamidinas utiles como inhibidores de la agregacion de plaquetas. | |
| LV12209A (lv) | Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori | |
| MA27664A1 (fr) | Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese | |
| ES2120728T3 (es) | Inhibidores de la agregacion de plaquetas. | |
| ATE227293T1 (de) | 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one | |
| DE69712042T2 (de) | Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten | |
| CY2204B1 (en) | Angiotensin ii antagonists as a prophylactic or therapeutic drug for renal diseases | |
| FI935800A0 (fi) | Antidepressiva och mot Parkisons sjukdom verksamma foereningar | |
| ES2110115T3 (es) | Inhibidores de la agregacion de plaquetas. | |
| BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
| DK0804418T3 (da) | Platelataggregationshæmmere | |
| KR970703301A (ko) | 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative) | |
| AR043271A1 (es) | Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa | |
| HUP0103113A2 (hu) | NOS inhibitorokat tartalmazó gyógyászati készítmények | |
| ES2049703T3 (es) | Derivados sulfurados de acidos biliares. | |
| ATE109485T1 (de) | Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
| ES2181879T3 (es) | Inhibidores de la agkytubacuib de las plaquetas que contienen restos de aminoacidos con cadenas laterales de c-terminal aminergicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |